A Novel Oncolytic Viral Therapy Using Coxsackievirus B3 (CVB3) for Human Pancreatic Cancer Including Cancer-associated Fibroblasts
CVB3 shows promise as an oncolytic virus effective against pancreatic cancer cells and CAFs, suggesting its potential as a novel virotherapy for pancreatic cancer. These findings highlight CVB3 as a candidate for further development as a therapeutic modality aimed at improving drug sensitivity and patient prognosis in pancreatic cancer.
Authors
- Kenzaburo Tani (ORCID: https://orcid.org/0000-0003-3335-6188)
- Atsushi Matsuzawa (ORCID: https://orcid.org/0000-0001-8303-3905)
- Akira Imaizumi (ORCID: https://orcid.org/0000-0002-8615-1007)
- Yutaka Fujioka (ORCID: https://orcid.org/0000-0002-8506-9343)
- Yusuke Hirata (ORCID: https://orcid.org/0000-0002-1428-2075)
- Hiroaki Niiro (ORCID: https://orcid.org/0000-0003-0914-9066)
- Hideya Onishi
- Hiroyuki Shimizu (ORCID: https://orcid.org/0000-0002-2987-2377)
- Masafumi Nakamura (ORCID: https://orcid.org/0000-0002-5584-8311)
- Hisanobu Ogata
- Toshihisa Tsuruta
Institutions
- Kyushu University (JP)
- Tohoku University (JP)
- National Institute of Infectious Diseases (JP)
- Nagoya University Hospital (JP)
- Kyushu University Hospital (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2024-12-01
- DOI
- https://doi.org/10.21873/anticanres.17348
- Citations
- 1
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.55